These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Efficacy and safety of latanoprost versus pilocarpine/timolol maleate fixed combination in patients with primary open-angle glaucoma or ocular hypertension.
    Author: Kałuzny J, Sobecki R, Czechowicz-Janicka K, Kecik D, Kałuzny BJ, Stewart JA, Stewart WC.
    Journal: Acta Ophthalmol; 2008 Dec; 86(8):860-5. PubMed ID: 18721251.
    Abstract:
    PURPOSE: This study aimed to compare the safety and effect on intraocular pressure (IOP) of latanoprost given every evening versus pilocarpine/timolol maleate fixed combination (PTFC) given twice daily in patients with primary open-angle glaucoma (POAG) or ocular hypertension (OH). METHODS: Following a 6-week, medicine-free period, qualified patients were randomized for Period 1 to either placebo administered every morning and latanoprost every evening or to PTFC administered twice daily. After 8 weeks of treatment, IOP was measured at 08.00, 10.00, 16.00 and 18.00 hours. Patients were then switched to the opposite treatment and underwent a second diurnal evaluation at the end of Period 2. RESULTS: Thirty-two patients completed this study. They demonstrated diurnal baseline IOP of 24.1 +/- 2.4 mmHg. Mean diurnal pressure was 16.8 +/- 2.1 mmHg on PTFC and 16.9 +/- 2.5 mmHg on latanoprost (p = 0.60). No statistical difference between treatments was observed at any individual time-point except at 10.00 hours, when the PTFC group demonstrated an IOP of 15.9 +/- 2.3 mmHg and latanoprost 16.8 +/- 2.7 mmHg (p = 0.02). There were no statistical differences between groups in unsolicited systemic or ocular adverse events (p > 0.05). However, the PTFC group showed a narrower pupil diameter (2.3 mm) than the latanoprost group (3.7 mm). Additionally, a solicited symptom survey demonstrated mild blurred vision, stinging and ocular pain with PTFC (p < 0.001). CONCLUSIONS: Both PTFC and latanoprost are efficacious in reducing diurnal IOP in POAG or OH. However, PTFC may be more effective in the late morning and may have a greater incidence of mild ocular side-effects.
    [Abstract] [Full Text] [Related] [New Search]